{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-26-000018","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2026-07-31T11:06:21+00:00","discovered_at":"2026-07-31T11:10:01.347552+00:00","generated_at":"2026-07-31T11:10:09.841423+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Werewolf Q2 net income $3.7M on $21M asset sale; cash runway into Q2 2027","bullets":["Net income of $3.7M vs net loss of $18.0M in Q2 2025; collaboration revenue of $21.0M from JZP898 sale to Jazz.","Cash and equivalents $22.0M as of June 30, 2026, down from $46.5M at March 31, 2026; expects to fund operations into Q2 2027.","R&D expenses decreased to $6.2M from $13.1M; G&A increased to $7.7M from $4.4M.","Exploring strategic alternatives with Piper Sandler; expects data updates on WTX-124 and WTX-330 in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-26-000018","json":"https://secwatch.observer/filing/0001785530-26-000018.json","markdown":"https://secwatch.observer/filing/0001785530-26-000018.md","text":"https://secwatch.observer/filing/0001785530-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/0001785530-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/howl-20260731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T11:10:09.841423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}